Who
Joseph Shulman
Chief Technical Officer
Company insider
Files Form 4 as: Chief Technical Officer, Rhythm Pharmaceuticals.
In numbers
- Trades disclosed
- 134
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $16.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Feb 2022
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $14K2,024 at $6.80 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $608K5,079 at $119.75 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,024 at $0.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,024 at $0.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $14K2,024 at $6.80 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $608K5,079 at $119.75 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —16,968 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $709K6,507 at $108.99 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,656 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,656 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,937 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,125 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,250 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,937 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,125 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,250 at $0.00 | filing |
News
Contrasting Rhythm Pharmaceuticals (NASDAQ:RYTM) & ADMA Biologics (NASDAQ:ADMA)RYTM · dailypolitical.com · 22 Oct 2026Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRYTM · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Joseph Shulman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.